NCT03736889 2026-04-22
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeOne Medicines
Phase 2 Recruiting
Clinical Trials
2,130 trialsNCT04123366 2026-04-22
MK-7339-007
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT05036291 2026-04-22
A Study of NB004 as Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors
Ningbo Newbay Technology Development Co., Ltd
Phase 1 Terminated
NCT06625593 2026-04-22
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06779851 2026-04-22
SUMMIT-1
Bright Peak Therapeutics Inc
Phase 1 Terminated
NCT07136779 2026-04-22
First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies
VelaVigo Bio Inc
Phase 1/2 Recruiting
NCT07299747 2026-04-22
Clinical Trial of VBC103 in Patients With Advanced Malignant Solid Tumors
VelaVigo Bio Inc
Phase 1/2 Recruiting
NCT07387068 2026-04-22
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Genmab
Phase 1 Recruiting
NCT07412613 2026-04-22
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Recruiting
NCT07545265 2026-04-22
SKB565 for Injection in Advanced Solid Tumors
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 1/2 Not yet recruiting
NCT03710876 2026-04-21
INFINITE
Ferring Ventures Limited
Phase 3 Completed
NCT05732831 2026-04-21
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06480552 2026-04-21
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Recruiting
NCT06532565 2026-04-21
Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors
Gilead Sciences
Phase 1 Recruiting
NCT07204340 2026-04-21
TLN-372 in Advanced KRAS Mutant Solid Tumors
Treeline Biosciences, Inc.
Phase 1 Recruiting
NCT07246863 2026-04-21
Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC
CatalYm GmbH
Phase 2 Recruiting
NCT07346846 2026-04-21
A Study of BGM-2121 in Patients With Advanced Solid Tumors
BioGate Precision Medicine Corp.
Phase 1 Recruiting
NCT07541001 2026-04-21
China Phase II
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT07541534 2026-04-21
A Phase I Clinical Study of HLX316 in Participants With Advanced/Metastatic Solid Tumors
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT04855656 2026-04-20
MYTHIC
Debiopharm International SA
Phase 1 Recruiting
NCT05571839 2026-04-20
A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
Seagen Inc.
Phase 1 Active not recruiting
NCT06659341 2026-04-20
A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation
Bayer
Phase 1 Recruiting
NCT06892379 2026-04-20
A Study of HS-20110 in Participants With Advanced Solid Tumors
Hansoh BioMedical R&D Company
Phase 1 Recruiting
NCT07446855 2026-04-20
PARTHENON
AstraZeneca
Phase 1/2 Recruiting
NCT07539285 2026-04-20
A Study of HDM2024 in Participants With Advanced Solid Tumors
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT03317743 2026-04-17
Study to Assess the Safety & Tolerability of NOV140101(IDX-1197) in Patients With Advanced Solid Tumors
Idience Co., Ltd.
Phase 1 Completed
NCT03881488 2026-04-17
Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
Compass Therapeutics
Phase 1 Completed
NCT04174716 2026-04-17
VASTUS
Idience Co., Ltd.
Phase 1/2 Completed
NCT06307795 2026-04-17
A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors
Avistone Biotechnology Co., Ltd.
Phase 1 Recruiting
NCT06365840 2026-04-17
TMB-H
ImmuneOncia Therapeutics Inc.
Phase 2 Recruiting
NCT06581432 2026-04-17
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
Boehringer Ingelheim
Phase 2 Recruiting
NCT06597721 2026-04-17
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Adcendo ApS
Phase 1 Recruiting
NCT07529535 2026-04-17
A First-in-Human Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors
Zhejiang Anglikang Pharmaceutical Co., Ltd.
Phase 1 Suspended
NCT07537881 2026-04-17
A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment of Solid Tumors
RemeGen Co., Ltd.
Phase 1/2 Not yet recruiting
NCT02934568 2026-04-16
Ribociclib (LEE011) Rollover Study for Continued Access
Novartis
Phase 2 Active not recruiting
NCT04241835 2026-04-16
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Ipsen
Phase 1 Terminated
NCT06082960 2026-04-16
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
Gilead Sciences
Phase 1 Active not recruiting
NCT07205718 2026-04-16
A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Takeda
Phase 1/2 Recruiting
NCT07266428 2026-04-16
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2 Recruiting
NCT07380334 2026-04-16
A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Recruiting
NCT07533708 2026-04-16
A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
Shanghai Henlius Biotech
Phase 1 Not yet recruiting
NCT07534813 2026-04-16
A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors
Grit Biotechnology
Phase NA Not yet recruiting
NCT04219254 2026-04-15
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
BioInvent International AB
Phase 1/2 Recruiting
NCT04886271 2026-04-15
Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 2 Completed
NCT05275478 2026-04-15
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
Tango Therapeutics, Inc.
Phase 1/2 Terminated
NCT05718895 2026-04-15
CLINCH
Antengene Corporation
Phase 1 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06596473 2026-04-15
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06741644 2026-04-15
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
CStone Pharmaceuticals
Phase 1/2 Recruiting
NCT07181681 2026-04-15
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting